Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform

DURHAM, N.C.–(BUSINESS WIRE)–Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced $7.8 million in additional funding from existing investors, the Dementia Discovery Fund and Illumina Ventures. Ribometrix also announced the appointment of Mike Clayman, M.D., as chairman of the board of directors. The new funding will support the continued development of the Ribometrix discovery platform, which uses sophisti